Atherosclerosis: Conventional intake of cardiovascular drugs versus delivery using nanotechnology - A new chance for...

Area of Science:

• Cardiovascular Research
• Nanomedicine
• Pharmacology

Background:

• Atherosclerosis is a leading cause of death, driven by macrophage immune responses to LDL deposition and endothelial dysfunction.
• Current cardiovascular drugs often fail to address the root cause of atherosclerosis, leading to limited efficacy.
• Statins and thiazolidinediones show promise for anti-atherosclerotic effects but suffer from poor site-specific delivery and off-target toxicity.

Purpose of the Study:

• To explore the potential of nanoparticulate carriers for enhancing the delivery of statins and thiazolidinediones in atherosclerosis treatment.
• To establish design criteria for nanoparticles to effectively target macrophages and endothelial cells within atherosclerotic plaques.
• To improve the therapeutic potential of existing drugs by optimizing their bioavailability at the pathological site.

Main Methods:

• Literature analysis to identify effective nanoparticle design principles for drug delivery.
• Evaluation of nanoparticle size requirements (below 100 nm) for plaque accumulation.
• Assessment of biodegradable materials for nanoparticle fabrication.
• Investigation of encapsulation strategies (core encapsulation) for optimal drug release and cellular uptake.
• Identification of surface ligands (e.g., targeting scavenger receptors or LOX1) for enhanced cellular targeting.

Main Results:

• Nanoparticles below 100 nm are crucial for accumulation within atherosclerotic plaques.
• Biodegradable materials are recommended for nanoparticle construction.
• Core encapsulation of statins and thiazolidinediones is necessary for their therapeutic mechanism, especially for thiazolidinediones.
• Surface ligands targeting scavenger receptors and LOX1 can significantly improve uptake into macrophages and endothelial cells.
• Targeted delivery enhances the anti-atherosclerotic effects of statins and thiazolidinediones.

Conclusions:

• Nanoparticulate drug delivery systems offer a promising strategy to overcome the limitations of current statin and thiazolidinedione therapies for atherosclerosis.
• Specific design criteria, including size, material, encapsulation, and surface functionalization, are essential for effective nanoparticle-based anti-atherosclerotic treatment.
• Targeting macrophages and endothelial cells via nanoparticle surface modification can significantly boost therapeutic outcomes and reduce side effects.